FOLH1 and posterior cortical atrophy: In this setting, it has been reported that in patients on AS, PSMA PET/CT has the ability to modify the treatment strategy: the presence of areas of higher tracer uptake should be further studied with biopsy to exclude the presence of high-grade PCa before endorsing follow-up [23].